CTOR (Citius Oncology, Inc. Common Stock) Stock Analysis - AI Report

Citius Oncology, Inc. Common Stock (CTOR) is a publicly traded Healthcare sector company. As of May 21, 2026, CTOR trades at $0.81 with a market cap of $77.07M and a P/E ratio of -2.37. CTOR moved -4.61% today. Year to date, CTOR is -28.17%; over the trailing twelve months it is -7.19%. Its 52-week range spans $0.49 to $6.19. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces CTOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on CTOR?

Rallies AI research for CTOR combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

CTOR Key Metrics

Key financial metrics for CTOR
MetricValue
Price$0.81
Market Cap$77.07M
P/E Ratio-2.37
EPS$-0.34
Dividend Yield0.00%
52-Week High$6.19
52-Week Low$0.49
Volume521
Avg Volume0
Revenue (TTM)$0
Net Income$-24.76M
Gross Margin0.00%

Latest CTOR News

CTOR Analyst Consensus

1 analysts cover CTOR: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.

Common questions about CTOR

What is the AI research view on CTOR?
Rallies AI research for CTOR combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for CTOR?
Rallies AI research for CTOR combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is CTOR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CTOR. It does not provide personalized investment advice.
CTOR

CTOR